We are live on ! Find out more
CTXR icon

Citius Pharmaceuticals
CTXR

56 hedge funds and large institutions have $18.9M invested in Citius Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 7 increasing their positions, 12 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,223% more call options, than puts

Call options by funds: $1.43M | Put options by funds: $108K

35% more capital invested

Capital invested by funds: $14M → $18.9M (+$4.9M)

0.04% less ownership

Funds ownership: 0.42% → 0.38% (-0.04%)

7% less funds holding

Funds holding: 60 → 56 (-4)

25% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 16

42% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 12

Holders
56
Holders Change
-4
Holders Change %
-6.67%
% of All Funds
0.96%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
7
Reduced
12
Closed
16
Calls
$1.43M
Puts
$108K
Net Calls
+$1.32M
Net Calls Change
+$926K

Top Buyers

Rank Fund Capital Flow
1
GCP
GSA Capital Partners
United Kingdom
+$155K
2
SG Americas Securities
SG Americas Securities
New York
+$98.4K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$87.5K
4
TSS
Two Sigma Securities
New York
+$51.2K
5
Group One Trading
Group One Trading
Illinois
+$47.5K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$1.05M
2
Goldman Sachs
Goldman Sachs
New York
-$203K
3
Citadel Advisors
Citadel Advisors
Florida
-$142K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$133K
5
E
Ergoteles
New York
-$79K
Name Holding Trade Value Shares
Change 		Change in
Stake
TSS
26
Two Sigma Securities
New York
$56K +$51.2K +1,862 New
Group One Trading
27
Group One Trading
Illinois
$52K +$47.5K +1,727 New
PAG
28
Private Advisor Group
New Jersey
$48K -$797 -29 -2%
Osaic Holdings
29
Osaic Holdings
Arizona
$44K +$2.2K +80 +6%
Jane Street
30
Jane Street
New York
$37K +$33.7K +1,225 New
Commonwealth Equity Services
31
Commonwealth Equity Services
Massachusetts
$33K – – –
T. Rowe Price Associates
32
T. Rowe Price Associates
Maryland
$28K – – –
CAG
33
Csenge Advisory Group
Florida
$18K – – –
US Bancorp
34
US Bancorp
Minnesota
$15K – – –
Man Group
35
Man Group
United Kingdom
$15K +$13.7K +500 New
BNP Paribas Financial Markets
36
BNP Paribas Financial Markets
France
$14K -$11.6K -423 -48%
PPW
37
Pasadena Private Wealth
California
$13K +$12.1K +439 New
RJFSA
38
Raymond James Financial Services Advisors
Florida
$13K +$12.2K +444 New
WJWM
39
Williams Jones Wealth Management
New York
$12K – – –
Wells Fargo
40
Wells Fargo
California
$6K – – –
CG
41
Cutler Group
California
$6K +$5.55K +202 +1,263%
TRCT
42
Tower Research Capital (TRC)
New York
$5K +$4.37K +159 New
APA
43
American Portfolios Advisors
New York
$4.84K – – –
Barclays
44
Barclays
United Kingdom
$4K -$3.54K -129 -49%
GIA
45
GHP Investment Advisors
Colorado
$4K – – –
SSC
46
Syverson Strege & Co
Iowa
$3K – – –
IA
47
IFP Advisors
Florida
$1K – – –
AIP
48
Almanack Investment Partners
Pennsylvania
$1K +$989 +36 New
FSWA
49
Financial Synergies Wealth Advisors
Texas
$242 – – –
TWC
50
TD Waterhouse Canada
Ontario, Canada
$121 – – –
1
2
3

CTXR Hedge Fund Activity: Q3 2022 in Review

56 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q3 2022, worth a combined $18.9M — up 35% from $14M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of CTXR and 12 opened new positions — a net loss of 4 holders — while 12 trimmed existing stakes and 7 added.

The largest buyer was GSA Capital Partners, opening a new position worth an estimated $155K. The largest seller was Millennium Management, cutting an estimated $1.05M.

  • 56 institutional investors held Citius Pharmaceuticals (CTXR) as of Q3 2022, down from 60 in Q2 2022.
  • Funds reported $18.9M of Citius Pharmaceuticals stock for Q3 2022, up 35% quarter-over-quarter.
  • 12 funds opened new Citius Pharmaceuticals positions in Q3 2022 and 16 closed out, a net change of -4 holders.
  • The largest Citius Pharmaceuticals buyer in Q3 2022 was GSA Capital Partners, an estimated $155K added.
  • The largest Citius Pharmaceuticals seller in Q3 2022 was Millennium Management, an estimated $1.05M sold.

Based on aggregated 13F filings for Q3 2022.